Asosiy kontentga oʻtish
Maqola

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Bertrand CariouDépartement d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France. [email protected]Samy HadjadjDépartement d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, France. [email protected]Matthieu WargnyDépartement d'Endocrinologie, Diabétologie et Nutrition, l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Hôpital Guillaume et René Laennec, 44093, Nantes Cedex 01, FranceMatthieu PichelinInsermAbdallah Al‐SalamehDépartement d'Endocrinologie, Diabétologie et Nutrition, CHU Amiens, PeriToxUMR_I 01, Université de Picardie, Amiens, FranceIngrid AllixDépartement d'Endocrinologie, Diabétologie, Nutrition, CHU de Angers, Angers, FranceCoralie AmadouDépartement de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil Essonne, FranceGwénaëlle ArnaultDépartement d'Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier Bretagne Atlantique, Vannes, FranceFlorence BaudouxHôpital Claude HuriezB. BauduceauFondation Francophone pour la Recherche sur le Diabète (FFRD), Paris, FranceSophie BorotDépartement d'Endocrinologie, Diabétologie et Nutrition, CHU de Besançon, Besançon, FranceMuriel Bourgeon‐GhittoriDépartement d'Endocrinologie, Diabétologie et Nutrition, Assistance Publique Hôpitaux de Paris, Université Paris Saclay, Hôpital Antoine Béclère, Clamart, Hôpital Bicêtre, Le Kremlin Bicêtre, FranceOlivier BourronFondation pour l’innovation en Cadiométabolisme et NutritionDavid BoutoilleF. RoblotSociété Française de CardiologieClaude ChaumeilFédération Française des Diabétiques (FFD), Paris, FranceEmmanuel CossonSorbonne Paris CitéSandrine CoudolCIC-EC 1413, Clinique des Données, CHU Nantes, Nantes, FrancePatrice DarmonDépartement d'Endocrinologie et de Diabétologie, Hôpital de la Conception, Assistance Publique Hôpitaux de Marseille, Marseille, FranceEmmanuel DisseLaboratoire de recherche en cardiovasculaire, métabolisme, diabétologie et nutritionAmélie Ducet‐BoiffardDépartement d'Endocrinologie et de Diabétologie, Centre Hospitalier Départemental de Vendée, La Roche sur Yon, FranceBénédicte GaboritDépartement d'Endocrinologie et de Diabétologie, Hôpital Nord, Assistance Publique Hôpitaux de Marseille, Marseille, FranceMichaël JoubertUniversité de Caen NormandieV. KerlanDépartement d'Endocrinologie, CHU de Brest, EA 3878 GETBO, Brest, FranceBruno LaviolleUniversité de Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), Rennes, FranceLucien MarchandDépartement d'Endocrinologie et de Diabétologie, Centre Hospitalier St. Joseph - St. Luc, Lyon, FranceLaurent MeyerDépartement d'Endocrinologie, Diabétologie et Nutrition, Hôpitaux Universitaires de Strasbourg, Strasbourg, FranceLouis PotierCentre de Recherche des CordeliersGaëtan PrévostDépartement d'Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Rouen, Université de Rouen, Rouen, FranceJean‐Pierre RivelineDépartement Diabète et Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, FranceRené RobertUniversité de PoitiersPierre‐Jean SaulnierUniversité de PoitiersAriane SultanDépartement d'Endocrinologie, Diabète, Nutrition et CIC Inserm 1411, CHU de Montpellier, Montpellier, FranceJean-François ThébautFédération Française des Diabétiques (FFD), Paris, FranceCharles ThivoletSociété Francophone du DiabèteBlandine TramuntDépartement d'Endocrinologie, Diabétologie et Nutrition, CHU Toulouse, Institut des Maladies Métaboliques et Cardiovasculaires, UMR1048 Inserm/UPS, Université de Toulouse, Toulouse, FranceCamille VatierAssistance Publique – Hôpitaux de ParisRonan RousselUniversité Paris CitéJean–François GautierCentre de Recherche des CordeliersPierre GourdyInstitut des Maladies Métaboliques et Cardiovasculairesfor the CORONADO investigators
2020en
ABI

Annotatsiya

Abstract Aims/hypothesis Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown. Methods We conducted a nationwide multicentre observational study in people with diabetes hospitalised for COVID-19 in 53 French centres in the period 10–31 March 2020. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Age- and sex-adjusted multivariable logistic regressions were performed to assess the prognostic value of clinical and biological features with the endpoint. ORs are reported for a 1 SD increase after standardisation. Results The current analysis focused on 1317 participants: 64.9% men, mean age 69.8 ± 13.0 years, median BMI 28.4 (25th–75th percentile: 25.0–32.7) kg/m 2 ; with a predominance of type 2 diabetes (88.5%). Microvascular and macrovascular diabetic complications were found in 46.8% and 40.8% of cases, respectively. The primary outcome was encountered in 29.0% (95% CI 26.6, 31.5) of participants, while 10.6% (9.0, 12.4) died and 18.0% (16.0, 20.2) were discharged on day 7. In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin–angiotensin–aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA 1c , diabetic complications or glucose-lowering therapies. In multivariable analyses with covariates prior to admission, only BMI remained positively associated with the primary outcome (OR 1.28 [1.10, 1.47]). On admission, dyspnoea (OR 2.10 [1.31, 3.35]), as well as lymphocyte count (OR 0.67 [0.50, 0.88]), C-reactive protein (OR 1.93 [1.43, 2.59]) and AST (OR 2.23 [1.70, 2.93]) levels were independent predictors of the primary outcome. Finally, age (OR 2.48 [1.74, 3.53]), treated obstructive sleep apnoea (OR 2.80 [1.46, 5.38]), and microvascular (OR 2.14 [1.16, 3.94]) and macrovascular complications (OR 2.54 [1.44, 4.50]) were independently associated with the risk of death on day 7. Conclusions/interpretations In people with diabetes hospitalised for COVID-19, BMI, but not long-term glucose control, was positively and independently associated with tracheal intubation and/or death within 7 days. Trial registration clinicaltrials.gov NCT04324736.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

3 ta iqtibos0 ta foydalanilgan manba